Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2 - Wikidata - wikimedia - TriplyDB

Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2

Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2

http://www.wikidata.org/entity/Q24649780

about

Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer Cancer and the blood-brain barrier: 'Trojan horses' for courses?Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.Novel delivery strategies for glioblastoma Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)Presumed LRP1-targeting transport peptide delivers β-secretase inhibitor to neurons in vitro with limited efficiency Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)Identification of peptide sequences that target to the brain using in vivo phage display.Agile delivery of protein therapeutics to CNS Clinical trials and progress with paclitaxel in ovarian cancer Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.Gene therapy for the nervous system: challenges and new strategies.Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1.The biology of brain metastases-translation to new therapies Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer Glioblastoma multiforme: novel therapeutic approaches Microtubule-severing ATPase spastin in glioblastoma: increased expression in human glioblastoma cell lines and inverse roles in cell motility and proliferation Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel.Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549)Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis.Breast cancer brain metastases: new directions in systemic therapy Paclitaxel Nano-Delivery Systems: A Comprehensive Review.Transport characteristics of a novel peptide platform for CNS therapeutics.Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.Microtubule dynamics as a target in oncology.New strategies to deliver anticancer drugs to brain tumors.Differential receptor-mediated drug targeting to the diseased brain.Targeted drug delivery for treatment and imaging of glioblastoma multiforme.Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma.Towards nanomedicines: design protocols to assemble, visualize and test carbon nanotube probes for multi-modality biomedical imaging.Receptor-mediated therapeutic transport across the blood-brain barrier.In vivo methods to study uptake of nanoparticles into the brain.Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier.Drug delivery to the CNS and polymeric nanoparticulate carriers.Shuttle-mediated drug delivery to the brain.

P2860

Q24621947-5F99FD66-DEBB-4793-8502-F926406CD882 Q24649731-87372DC7-36F3-4BD1-9A82-AE739226FD70 Q26778701-616204CC-E6BB-4062-80F4-9D5B4AC6762B Q27006099-1E37201F-BBF4-40BF-A5DE-287D0A3A1F07 Q27300391-82495D88-614F-43EB-B91A-EC6FC0303F1F Q27341864-4E4086B3-0BDC-473C-A5A2-9FFBFD20A081 Q28829762-E88A1322-B194-4AA7-B4F1-57A699FA2304 Q30572687-A1711141-1471-40DB-8E1D-995641EE7FC2 Q33578254-41085192-6E80-4850-947B-1074B84C423E Q33972613-4EFA7259-94A5-4343-B1D8-CCB27AF1797A Q34079647-E05B1A95-9A4E-4049-B7A2-39435AA2C458 Q34510070-51CB8349-8959-4325-8397-87428C8B5180 Q35222776-47FDA478-2002-416E-B081-55705B5AA6DB Q35237773-705841F8-15E2-41F7-B8E9-D1FD348CCD89 Q35340196-917B5EBE-ACE3-4E95-9251-CF6E75A715BB Q35623290-7FC60BF8-6AA3-4975-9F2D-A7E9F796433B Q35676602-A9BB79D6-CDB2-4BD9-89AB-6CA94941EBC6 Q35683264-96CF8E6C-9A8B-42D7-B810-019D42356235 Q35805489-D2DE891E-C2A8-4D1E-A4F8-4EDC977B2F52 Q35825491-FB09956C-D333-4D1B-94F6-BB1CB3043A34 Q36104749-B0464823-3C94-4E9D-9787-06F9FE84536D Q36280722-F20EC61A-95CF-459F-803E-8F93BADE2A13 Q36311218-EE071DC9-96D8-4E7D-9F8B-F0BDD6C417CA Q36333938-8D7F6B89-490E-4EEC-86C9-D54A891351C1 Q36822500-1EDFCD49-67C7-43A1-9053-5061E9E3FCE7 Q37250009-E948BC35-3B80-4BFD-9E16-BC86A6F74F00 Q37294333-F338A458-7B83-4B95-9EE0-DF4FFB2E646D Q37312010-839C9527-D844-4CA9-9169-91A4E01A29D7 Q37360708-B47EC32D-719E-4769-B2DA-A3382C715463 Q37364700-CB9B286C-9D98-45DF-A019-6D6FC95914B6 Q37425213-61282937-A8DA-421A-A6F0-9394AB17E820 Q37523966-F34B10EC-9C67-49D3-A59A-C67A4EA407AD Q37694794-F53E40C3-20CF-43F9-85E5-B66F7E7F351C Q37770188-CA27437B-93BA-4C0D-B8DA-99D940849E6C Q37773246-A8FF00E5-E3BA-46FF-871A-7E7AB1C98F01 Q37798178-5AFD36F7-586D-4C23-B21E-182CAC872553 Q37841631-452C06C2-1CFC-437E-AE01-EAB8246980E0 Q37855817-CEEE9B25-BA39-4279-AF27-0146D117E67D Q37856301-E5B319B7-4EBC-4D17-A5AA-6AD3BFAB12A2 Q37896550-4DDC9B1E-3878-4F78-A81D-81C7E2BCD1B1

P2860

Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2

http://www.wikidata.org/entity/Q24649780

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Antitumour activity of ANG1005 ...... ain delivery vector Angiopep-2

@ast

Antitumour activity of ANG1005 ...... ain delivery vector Angiopep-2

@en

Antitumour activity of ANG1005 ...... ain delivery vector Angiopep-2

@nl

type

label

Antitumour activity of ANG1005 ...... ain delivery vector Angiopep-2

@ast

Antitumour activity of ANG1005 ...... ain delivery vector Angiopep-2

@en

Antitumour activity of ANG1005 ...... ain delivery vector Angiopep-2

@nl

prefLabel

Antitumour activity of ANG1005 ...... ain delivery vector Angiopep-2

@ast

Antitumour activity of ANG1005 ...... ain delivery vector Angiopep-2

@en

Antitumour activity of ANG1005 ...... ain delivery vector Angiopep-2

@nl

P1433

Q24649780-0C5F84D0-4A69-4AF8-A5A7-733B44F29528

P1476

Q24649780-35D86E9D-EC78-424D-8F40-15AB662DB2FA

P2093

Q24649780-17B2241B-D107-42B4-BD07-DADE488DFA8E

Q24649780-33465224-E15D-420C-9E05-8050D529473A

Q24649780-8CACDFD9-93FE-4974-A689-C6282210EA28

Q24649780-B86CB00E-F117-4F31-A5AF-B34AED7A5E74

Q24649780-D11CD552-0C93-4BD3-8B90-772CA6D6CFA6

Q24649780-DD4D9241-86D5-4579-9591-86A2891160D3

Q24649780-EBDBCC0B-A001-4DEA-828B-B82C3C338E5C

Q24649780-FF48582D-CD01-4354-8341-7911A0B60607

P2860

Q24649780-0C3C07F1-4B1D-4EC1-9C62-82C03E30417E

Q24649780-0E261B9C-BDA0-4B96-A50F-8AD2841E7635

Q24649780-0EF94223-731F-410F-8993-A3E6CA0D0951

Q24649780-14BBBCD8-7251-4564-B7FE-1C1E546C2437

Q24649780-16060B26-AC34-489A-897E-F416B05172A1

Q24649780-1D22A2CE-8BC8-4EA4-9FC5-D60D53B1C9D0

Q24649780-2A83C070-9569-47DB-B0A5-19F152C13669

Q24649780-3DD1BAA0-8410-48EC-ABDF-B8383E0B5431

Q24649780-4BA26C42-9BE9-4D3A-B2EE-C00543B2FCD2

Q24649780-4FA95EF3-BFFE-4D1B-B210-3F30E0B4AE5F

P304

Q24649780-FFBEF969-7C30-4A89-8675-FD249E229489

P31

Q24649780-EBDB2291-6D1E-46E9-AF0C-ED40A4B573DF

P3181

Q24649780-8409CBF4-3D2D-4E20-A448-4A10F8AB5514

P356

Q24649780-730349EE-F2A3-49D5-BF6E-72B4D5384CBC

P407

Q24649780-9CAD6AB2-B399-44D5-AEF5-D99A3D377EB4

P433

Q24649780-768F44CA-9450-4D19-B76F-B8C354F8F461

P478

Q24649780-8B025B1F-6AD9-4A24-8C31-5E1BFAA780A0

P577

Q24649780-C9E2A326-8613-411F-B44B-2852267D5460

P5875

Q24649780-19A3AAC3-D198-4774-8504-611BBA8C4F0F

P698

Q24649780-FCFCDC02-DB26-486E-8624-E283D76B78D3

P921

Q24649780-1E224F57-29BE-4779-B539-0BDD6291AC55

P932

Q24649780-B32DDF82-B293-4343-B4A1-0AB0715E689E

P3181

P356

P1433

British Journal of Pharmacology

P1476

Antitumour activity of ANG1005 ...... ain delivery vector Angiopep-2

@en

P2093

A Régina

http://www.w3.org/2001/XMLSchema#string

C Ché

http://www.w3.org/2001/XMLSchema#string

I Lavallée

http://www.w3.org/2001/XMLSchema#string

J Poirier

http://www.w3.org/2001/XMLSchema#string

J-P Castaigne

http://www.w3.org/2001/XMLSchema#string

M Demeule

http://www.w3.org/2001/XMLSchema#string

R Béliveau

http://www.w3.org/2001/XMLSchema#string

R Gabathuler

http://www.w3.org/2001/XMLSchema#string

P2860

High transcytosis of melanotransferrin (P97) across the blood-brain barrier

Nanoparticles of biodegradable polymers for clinical administration of paclitaxel.

Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.

Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas.

Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme.

Salvage chemotherapy with paclitaxel for recurrent primary brain tumors.

New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy.

The taxanes: an update.

ABC transporters and the blood-brain barrier.

Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

P304

185-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3280424

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/BJP.2008.260

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

155

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5280804

http://www.w3.org/2001/XMLSchema#string

P698

18574456

http://www.w3.org/2001/XMLSchema#string

P921

P932

2538693

http://www.w3.org/2001/XMLSchema#string